Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
3.460
+0.025 (0.73%)
At close: Jan 8, 2026, 4:00 PM EST
3.371
-0.089 (-2.58%)
After-hours: Jan 8, 2026, 5:25 PM EST
Processa Pharmaceuticals Employees
Processa Pharmaceuticals had 10 employees as of December 31, 2024. The number of employees decreased by 3 or -23.08% compared to the previous year.
Employees
10
Change (1Y)
-3
Growth (1Y)
-23.08%
Revenue / Employee
n/a
Profits / Employee
-$1,293,360
Market Cap
7.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10 | -3 | -23.08% |
| Dec 31, 2023 | 13 | -2 | -13.33% |
| Dec 31, 2022 | 15 | 0 | - |
| Dec 31, 2021 | 15 | 1 | 7.14% |
| Dec 31, 2020 | 14 | 1 | 7.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PCSA News
- 3 days ago - Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study - GlobeNewsWire
- 22 days ago - Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data? - Benzinga
- 22 days ago - Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer - GlobeNewsWire
- 2 months ago - Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 - GlobeNewsWire
- 5 months ago - Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies - GlobeNewsWire
- 6 months ago - Processa Pharmaceuticals Provides Portfolio and Business Update - GlobeNewsWire
- 7 months ago - Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering - GlobeNewsWire
- 7 months ago - Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate - GlobeNewsWire